Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03916003
Other study ID # 19-3288
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 18, 2019
Est. completion date July 30, 2022

Study information

Verified date November 2023
Source Menzies School of Health Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed as a multi-centre randomized, open label trial to compare the safety and efficacy of a high dose primaquine (PQ) treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P. vivax episodes to current standard practice of providing only schizontocidal treatment.


Description:

Plasmodium vivax forms dormant liver stages that reactivate weeks or months following an acute infection. Recurrent infections can be associated with a febrile illness, a cumulative risk of severe anaemia, direct and indirect mortality, and are the most important source of onward transmission of the parasite. In co-endemic areas, there is a very high risk (up to 50%) of patients representing with P. vivax malaria following treatment of P. falciparum. Hence, in co-endemic regions there is a strong rationale for eradicating P. vivax hypnozoites from the liver in patients presenting with uncomplicated P. falciparum infections. The recently completed multicentre IMPROV study compared the efficacy of a 7 day primaquine regimen (1.0 mg/kg/day for 7 days) with a 14 day regimen (0.5 mg/kg/day for 14 days). The 7 day PQ regimen was non-inferior to the 14 day regimen and 5-fold more efficacious at reducing P. vivax recurrence than the control. This study is designed as a multicentre randomized, open label trial to compare the safety and efficacy of a high dose PQ treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P. vivax episodes to current standard practice of providing only schizontocidal treatment.


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date July 30, 2022
Est. primary completion date May 14, 2022
Accepts healthy volunteers No
Gender All
Age group 1 Year and older
Eligibility Inclusion Criteria: - P. falciparum mono-infection - Fever (axillary temperature =37.5°C) or history of fever in preceding 48 hours - Age >1 years (= 18 years at the Ethiopia site) - G6PD normal as defined by the Biosensor (SD Biosensor, ROK) at =70% of the adjusted male median (AMM) for each site - Written informed consent - Able to comply with all study procedures and timelines Exclusion Criteria: - General danger signs or symptoms of severe malaria - Anaemia, defined as Hb <8g/dl - Pregnant women as determined by Urine ß-HCG pregnancy test - Breast feeding women - Known hypersensitivity to any of the drugs given - Regular use of drugs with haemolytic potential - Blood transfusion within the last 4 months

Study Design


Intervention

Drug:
primaquine
Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)

Locations

Country Name City State
Bangladesh Icddrb Upazila
Ethiopia Arba Minch University Arba Minch
Indonesia Puskesmas Mangili Dusun Tenggara

Sponsors (5)

Lead Sponsor Collaborator
Menzies School of Health Research Addis Ababa University, Arba Minch University, International Centre for Diarrhoeal Disease Research, Bangladesh, Tribhuvan University, Nepal

Countries where clinical trial is conducted

Bangladesh,  Ethiopia,  Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence risk of any P. vivax parasitaemia at day 63 The incidence risk of any P. vivax parasitaemia at day 63 63 days
Secondary Incidence risk of symptomatic P. vivax parasitaemia at day 63 incidence risk of symptomatic P. vivax parasitaemia at day 63 63 days
Secondary Incidence risk of all any P. vivax parasitaemia at day 28 and 42 Incidence risk of all any P. vivax parasitaemia at day 28 and 42 28 and 42 days
Secondary Incidence risk of any P. falciparum malaria at day 28, 42 and 63 incidence risk of any P. falciparum malaria at day 28, 42 and 63 28/42/63 days
Secondary proportion of patients vomiting their medication within 1 hour of administration proportion of patients vomiting their medication on the day of enrollment within 1 hour of administration 1 hour
Secondary proportion of patients vomiting any of their PQ doses within 1 hour of administration proportion of patients vomiting any of their PQ doses within 1 hour of administration 7 days
Secondary proportion of adverse events and serious adverse events proportion of adverse events and serious adverse events 63 days
Secondary incidence risk of severe anaemia (Hb<5g/dl) and moderately severe anaemia (<7g/dl) and/or the risk for blood transfusion between day 3 and 7 incidence risk of severe anaemia (Hb<5g/dl) and moderately severe anaemia (<7g/dl) and/or the risk for blood transfusion between day 3 and 7 7 days
Secondary • The incidence risk of =25% fall in haemoglobin since baseline with and without hemoglobinuria at day 3 and day 7 • The incidence risk of =25% fall in haemoglobin since baseline with and without hemoglobinuria at day 3 and day 7 7 days
Secondary The incidence risk of =25% fall in haemoglobin to under 7g/dl with and without hemoglobinuria at day 3 and day 7 The incidence risk of =25% fall in haemoglobin to under 7g/dl with and without hemoglobinuria at day 3 and day 7 day 7
Secondary Incidence risk of P. falciparum gametocytaemia between day 7 and 63 Incidence risk of P. falciparum gametocytaemia between day 7 and 63 63 days
Secondary Parasite clearance on day 1, 2 and 3 Parasite clearance on day 1, 2 and 3 3 days
Secondary Fever clearance on day 1, 2 and 3 Fever clearance on day 1, 2 and 3 3 days
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Completed NCT02527005 - A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients Phase 1